论文部分内容阅读
目的:观察氨氯地平治疗高血压合并冠心病的疗效。方法:将高血压合并冠心病300例随机分为观察组和对照组各150例。观察组和对照组分别给予氨氯地平和贝那普利治疗,采用颈动脉超声测定颈动脉内膜中层厚度(IMT),随访记录治疗期间的不良心脑血管事件。结果:观察组和对照组血压下降均非常显著(P<0.01),但两组比较,差异不显著(P>0.05)。治疗12个月后颈动脉IMT,观察组较对照组显著减少(P<0.05)。在降低主要不良心脑血管事件发生率方面,观察组显著低于对照组(P<0.05),但在减少行血运重建术及心力衰竭方面,两组差异不显著(P>0.05)。结论:氨氯地平对于血压控制疗效肯定,在减慢颈动脉粥样硬化病变进展、减少主要不良心脑血管事件方面均优于贝那普利。
Objective: To observe the efficacy of amlodipine in the treatment of hypertension complicated with coronary heart disease. Methods: 300 patients with hypertension and coronary heart disease were randomly divided into observation group and control group, 150 cases each. The observation group and the control group were treated with amlodipine and benazepril respectively. The carotid artery intima-media thickness (IMT) was measured by carotid ultrasonography. The adverse cardiovascular and cerebrovascular events were recorded during follow-up. Results: The decrease of blood pressure in the observation group and the control group were all significant (P <0.01), but there was no significant difference between the two groups (P> 0.05). After 12 months of treatment, carotid IMT was significantly decreased in the observation group compared with the control group (P <0.05). The observation group was significantly lower than the control group in reducing the incidence of major adverse cardiovascular events (P <0.05), but there was no significant difference between the two groups in reducing revascularization and heart failure (P> 0.05). Conclusion: Amlodipine is effective for blood pressure control and is better than benazepril in slowing down the progression of carotid atherosclerosis and reducing the major adverse cardiac and cardiovascular events.